Disease Modification in Rheumatoid Arthritis - The Biologics Boom

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The global Rheumatoid Arthritis (RA) market has experienced extraordinary growth over the last decade. This market valued at $4.14 billion in 2004, shows no hint of decline. The explosion in new disease modifying drugs since the late 1990's has resulted in a competitive and rapidly evolving market. However, the recent events in the COX-2 market will continue to impact all arthritis drugs.


Scope

  • Detailed analysis of traditional and biologic DMARDs, with sales and volume forecasts to 2014 for the RA indication alone
  • Assessment of current and future opportunities and threats in the RA market across the seven major pharmaceutical markets
  • Consideration of key events that may affect revenues in each of the seven major pharmaceutical markets are applied and discussed
  • Lifecycle management case studies show how previously successful strategies should be applied in today's market


    • Report Highlights
    The key indications required by a new disease-modifying treatment include improvement in physical function, reducing signs and symptoms and inhibiting structural progression. Additional indications in the treatment of early RA and juvenile idiopathic arthritis would allow a new product to compete with the now well-established TNF inhibitors.

    The launch of new treatments at a premium cost appears to confer a superior treatment, as exemplified by Abbott's launch of Humira. The variation in key product pricing across different countries for a year of treatment shows that careful selection of launch price is needed to make the product competitive and also ensure good returns.

    Japan, as the last market forecast to launch most of the biologics, lags behind and is predicted to show slower uptake of these products. However, the recent launch of Enbrel and forecast launch of Humira in this market is expected to push the biologic class above traditional DMARDs by 2010 in this region.


    Reasons to Purchase

  • Assess the impact of events such as Medicare changes, patent expiries and sub-indication approvals on the RA sales of key brand name products
  • Quantify the future size of the market, in terms of volume and value, for the RA indication in each of the seven major markets
  • Gain insight into opinion leaders thoughts on the challenges facing the RA market

    • Table of Contents

    Other users found this report page using the following search terms: rheumatoid arthritis autoimmune arthritis biologics rheumatoid patent ra market enbrel remicade launch humira

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.